Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER.
CECLOR CD vs CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
1-2 g IV every 6-8 hours. Maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
Renal: ~80% unchanged; biliary/fecal: ~20%
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic